Usefulness of recombinant human TSH aided radioiodine doses administered in patients with differentiated thyroid carcinoma

Medicina

Volumn 66, Issue 2, 2006, Pages 125-130

  Pitoia, Fabian ^a,c   El Tamer, Elias ^a   Schere, Daniel B ^b   Passerieu, Mariano ^a   Bruno, Oscar D ^a   Niepomniszcze, Hugo ^a  

^a HOSPITAL DE CLÍNICAS JOSÉ DE SAN MARTÍN   (Argentina)

^b Laboratorio de Medicina Nuclear   (Argentina)

^c Laboratorio de Medicina Nuclear ^*  (Argentina)

Author keywords

Cancer; Recombinant TSH; rhTSH; Thyroid; Treatment

Indexed keywords

IODINE 131; LEVOTHYROXINE; RECOMBINANT THYROTROPIN; THYROGLOBULIN;

ABSENCE OF SIDE EFFECTS; ADULT; AGED; CANCER MORTALITY; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG EFFICACY; DRUG WITHDRAWAL; FEMALE; FOLLOW UP; HORMONAL REGULATION; HUMAN; LUNG METASTASIS; MALE; MEDIASTINUM METASTASIS; NECK METASTASIS; PATHOLOGY; QUALITY OF LIFE; REVIEW; THYROID CARCINOMA; TUMOR DIFFERENTIATION; WHOLE BODY SCINTISCANNING;

ADULT; AGED; AGED, 80 AND OVER; CARCINOMA; FEMALE; FOLLOW-UP STUDIES; HUMANS; IODINE RADIOISOTOPES; MALE; MIDDLE AGED; RECOMBINANT PROTEINS; THYROGLOBULIN; THYROID NEOPLASMS; THYROTROPIN; TREATMENT OUTCOME; WHOLE-BODY COUNTING;

EID: 33646689169     PISSN: 00257680     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (53)

1. Schlumberger MJ. Papillary and follicular thyroid carcinoma. N Engl J Med 1998; 338: 297-306.
2. Mazzaferri E, Massoll N. Management of papillary and follicular (differentiated) thyroid cancer: new paradigms using recombinant human thyrotropin. Endocr Relat Cancer 2002; 9: 227-47.
3. 131I uptake postthyroidectomy for thyroid cancer. J Clin Endocrinol Metab 1980; 50: 734-9.
4. Schlumberger M, Charbord P, Fragu P, et al. Relationship between thyrotropin stimulation and radioiodine uptake in lung metastases of differentiated thyroid carcinoma. J Clin Endocrinol Metab 1983; 57: 148-51.
5. Dow KH, Ferrel BR, Anello C. Quality of life changes in patients with thyroid cancer after withdrawal of thyroid hormone therapy. Thyroid 1997; 7: 613-9.
6. Goldberg LD, Ditchek NT. Thyroid carcinoma with spinal cord compression. JAMA 1981; 245: 953-4.
7. Meier CA, Braverman LE, Ebner SA, et al. Diagnostic use of recombinant human thyrotropin in patients with thyroid carcinoma (Phase I/II Study). J Clin Endocrinol Metab 1994; 78: 188-96.
8. Ladenson PW, Braverman LE, Mazzaferri EL, et al. Comparison of administration of recombinant human thyrotropin with withdrawal of thyroid hormone for radioactive iodine scanning in patients with thyroid carcinoma. N Engl J Med 1997; 337: 888-95.
9. Haugen BR, Pacini F, Reiners C, et al. A comparison of recombinant human thyrotropin and thyroid hormone withdrawal for the detection of thyroid remnant or cancer. J Clin Endocrinol Metab 1999; 84: 3877-85.
10. Mazzaferri EL, Robbins RJ, Spencer CA, et al. A consensus report of the role of serum thyroglobulin as a monitoring method for low-risk patients with papillary thyroid carcinoma. J Clin Endocrinol Metab 2003; 88: 1433-41.
11. Schlumberger M, Berg G, Cohen O, et al. Follow-up of low-risk patients with differentiated thyroid carcinoma: a European perspective. Eur J Endocrinol 2004; 150: 105-12.
12. Luster M, Lippi F, Jarzab B, et al. rhTSH-aided radioiodine ablation and treatment of differentiated thyroid carcinoma: a comprehensive review. Endocr Relat Cancer 2005; 12: 49-64.
13. Pitoia F, Degrossi OJ, Niepomniszcze H. Why should the radioiodine dose be different in patients with differentiated thyroid carcinoma prepared with recombinant human TSH? Eur J Nucl Med Mol Imaging 2004; 31: 924; author reply: 924-5.
14. Pitoia F, Niepomniszcze H. Tumor growth after recombinant human TSH. Clin Endocrinol (Oxf) 2002; 57: 301.
15. Niepomniszcze H, Schere D. How to distinguish between radioiodine accumulation in a laryngocele from a radioiodine-concentrating thyroid remnant after thyroidectomy for papillary carcinoma. Thyroid 2004; 14: 867-8.
16. Robbins RJ, Tuttle RM, Sonenberg M, et al. Radioiodine ablation of thyroid remnants after preparation with recombinant human thyrotropin. Thyroid 2001; 11: 865-9.
17. Robbins RJ, Larson SM, Sinha N, et al. A retrospective review of the effectiveness of recombinant human TSH as preparation for radioiodine thyroid remnant ablation [brief communication]. J Nucl Med 2002; 43: 1482-8.
18. Berg G, Lindstedt G, Suurküla M, Jansson S. Radioiodine ablation and therapy in differentiated thyroid cancer under stimulation with recombinant human thyroid-stimulating hormone (rhTSH). J Endocrinol Invest 2002; 25: 44-52.
19. Pacini F, Molinaro E, Castagna MG, et al. Ablation of thyroid residues with 30 mCi 1311: a comparison in thyroid cancer patients prepared with recombinant human TSH or thyroid hormone withdrawal. J Clin Endocrinol Metab 2002; 87: 4063-8.
20. Barbaro D, Boni G, Meucci G, et al. Radioiodine treatment with 30 mCi after recombinant human thyrotropin stimulation in thyroid cancer: effectiveness for postsurgical remnants ablation and possible role of iodine content in L-thyroxine in the outcome of ablation. J Clin Endocrinol Metab 2003; 88: 4110-5.
21. Kovatcheva RD, Hadjieva TD, Kirilov GG & Lozanov BS. Recombinant human TSH in radioiodine treatment of differentiated thyroid cancer. Nucl Med Rev Cent East Eur 2004; 7: 13-9.
22. Pacini F, Ladenson P, Schlumberger M, et al. Preparation with thyrotropin alfa is equivalent to thyroid hormone withdrawal as preparation for thyroid remnant ablation in differentiated thyroid carcinoma. Turk J Endocrinol Metab 2004; 8: 21.
23. Luster M, Sherman SI, Skarulis MC, et al. Comparison of radioiodine biokinetics following the administration of recombinant human thyroid stimulating hormone and after thyroid hormone withdrawal in thyroid carcinoma. Eur J Nucl Med Mol Imaging 2003; 30: 1371-7.
24. Adler ML, Macapinlac HA, Robbins RJ. Radioiodine treatment of thyroid cancer with the aid of recombinant human thyrotropin. Endocr Pract 1998; 4: 282-6.
25. Rudavsky AZ, Freeman LM. Treatment of scannegative, thyroglobulin-positive metastatic thyroid cancer using radioiodine 131l and recombinant human thyroidstimulating hormone [clinical case seminar]. J Clin Endocrinol Metab 1998; 82: 11-4.
26. Colleran KM, Burge MR. Isolated thyrotropin deficiency secondary to primary empty sella in a patient with differentiated thyroid carcinoma: an indication for recombinant thyrotropin. Thyroid 1999; 9: 1249-52.
27. Masiukiewicz US, Nakchbandi IA, Stewart AF, Inzucchi SE. Papillary thyroid carcinoma metastatic to the pituitary gland. Thyroid 1999; 9: 1023-7.
28. Vargas GE, Uy H, Bazan C, Guise TA, Bruder JM. Hemiplegia after thyrotropin alfa in a hypothyroid patient with thyroid carcinoma metastatic to the brain. J Clin Endocrinol Metab 1999; 84: 3867-71.
29. Perros P. Recombinant human thyroid-stimulating hormone (rhTSH) in the radioablation of well-differentiated thyroid cancer: preliminary therapeutic experience. J Endocrinol Invest 1999; 22: 30-4.
30. Luster M, Lassmann M, Haenscheid M, Michalowski U, Incerti C, Reiners C. Use of recombinant human thyrotropin before radioiodine therapy in patients with advanced differentiated thyroid carcinoma. J Clin Endocrinol Metab 2000; 85: 3640-5.
31. Mariani G, Ferdeghini M, Augeri C, et al. Clinical experience with recombinant human thyrotropin (rhTSH) in the management of patients with differentiated thyroid cancer. Cancer Biother Radiopharm 2000; 15: 211-7.
32. Robbins RJ, Voelker E, Wang W, Macapinlac HA, Larson SM Compassionate use of recombinant human thyrotropin to facilitate radioiodine therapy: case report and review of the literature. Endocr Pract 2000; 6: 460-4.
33. Lippi F, Capezzone M, Angelini F, et al. Radioiodine treatment of differentiated thyroid cancer on L-thyroxine plus recombinant human TSH (rhTSH): initial single-center experience. Eur J Endocrinol 2001; 144: 5-11.
34. Pellegritti G, Scollo C, Giuffrida D, Vigneri R, Squatrito S, Pezzino V. Usefulness of recombinant human thyrotropin in the radiometabolic treatment of selected patients with thyroid cancer. Thyroid 2001; 11: 1025-30.
35. Jarzab B, Handkiewicz-Junak D, Roskosz J, et al. Recombinant human TSH-aided radioiodine treatment of advanced differentiated thyroid cancer: single-center study of 54 patients. Eur J Nucl Med Mol Imaging 2003; 30: 1077-86.
36. Rotman-Pikielny P, Reynolds JC, Barker WC, Yen PM, Skarulis MC, Sarlis NJ Recombinant human thyrotropin for the diagnosis and treatment of a highly functional metastatic struma ovarii. J Clin Endocrinol Metab 2000; 85: 237-44.
37. Aslam SN, Daly RG. Use of recombinant human thyrotropin in a complicated case of metastatic papillary thyroid carcinoma. Endocr Pract 2001; 7: 99-101.
38. Checrallah A, Medlej R, Saade C, Khayat G, Halaby G. Malignant struma ovarii: an unusual presentation [case history]. Thyroid 2001; 11: 889-92.
39. Berg G, Lindstedt G, Suurküla M, Jansson S. Radioiodine ablation and therapy in differentiated thyroid cancer under stimulation with recombinant human thyroid-stimulating hormone (rhTSH). J Endocrinol Invest 2002; 25: 44-52.
40. Müller V, Bohuslavizki KH, Klutmann S, Clausen M. Value of recombinant human thyrotropin in high-dose radioiodine therapy: a case report. J Nucl Med Technol 2002; 30: 185-8.
41. Goffman T, Ioffe V, Tuttle M, Bowers JT, Mason ME. Near-lethal respiratory failure after recombinant human thyroid-stimulating hormone use in a patient with metastatic thyroid carcinoma [case history]. Thyroid 2003; 13: 827-30.
42. de Keizer B, Brans B, Hoekstra A, et al. Tumour dosimetry and response in patients with metastatic differentiated thyroid cancer using recombinant human thyrotropin before radioiodine therapy. Eur J Nucl Med Mol Imaging 2003; 30: 367-73.
43. Menzel C, Kranert WT, Döbert N, et al. rhTSH stimulation before radioiodine therapy in thyroid cancer reduces the effective half-life of 131I. J Nucl Med 2003; 44: 1065-8.
44. Driedger AA, Kotowycz N. Two cases of thyroid carcinoma that were not stimulated by recombinant human thyrotropin [clinical case seminar]. J Clin Endocrinol Metab 2004; 89: 585-90.
45. Taïeb D, Jacob T, Zotian E, Mundler O. Lack of efficacy of recombinant human thyrotropin versus thyroid hormone withdrawal for radioiodine therapy imaging in a patient with differentiated thyroid carcinoma lung metastases [case history]. Thyroid 2004; 14: 465-7.
46. Ashcraft MW, Van Herle AJ. The comparative value of serum thyroglobulin measurements and iodine 131 total body scans in the follow-up study of patients with treated differentiated thyroid cancer. Am J Med 1981; 71: 806-14.
47. Ronga G, Filesi M, Ventroni G, Vestri AR, Signore A. Value of the first serum thyroglobulin level after total thyroidectomy for the diagnosis of metastases from differentiated thyroid carcinoma. Eur J Nucl Med 1999; 26: 1448-52.
48. Franceschi M, Kusic Z, Franceschi D, Lukinac L, Roncevic S. Thyroglobulin determination, neck ultrasonography and iodine-131 whole-body scintigraphy in differentiated thyroid carcinoma. J Nucl Med 1996; 37: 446-51.
49. Montella L, Caraglia M, Abbruzzese A, et al. Molecular technology and the recombinant TSH have changed diagnostics of thyroid carcinoma with positive I-131 whole body scan but low serum thyroglobulin. Exp Mol Med 2004; 36: 268-73.
50. Muller-Gartner HW, Schneider C. Clinical evaluation of tumor characteristics predisposing serum thyroglobulin to be undetectable in patients with differentiated thyroid cancer. Cancer 1988; 61: 976-81.
51. Ronga G, Fiorentino A, Paserio E, et al. Can iodine-131 whole-body scan be replaced by thyroglobulin measurement in the post-surgical follow-up of differentiated thyroid carcinoma? J Nucl Med 1990; 31: 1766-71.
52. Schneider AB, Ikekubo K, Kuma K. Iodine content of serum thyroglobulin in normal individuals and patients with thyroid tumors. J Clin Endocrinol Metab 1983; 57: 1251-56.
53. Kohno Y, Tarutani O, Sakata S, Nakajima H. Monoclonal antibodies to thyroglobulin elucidate differences in protein structure of thyroglobulin in healthy individuals and those with papillary adenocarcinoma. J Clin Endocrinol Metab 1985; 61: 343-50.